Early Access Care is proud to sponsor and participate as a presenter at the 5th Operationalize Expanded Access Programs Summit, taking place in Boston on March 19 and 20. This summit brings together industry leaders, healthcare professionals, and regulatory experts to discuss the latest...

Early Access Care focuses on supporting caregivers and families by working with patients and advocates to develop programs for access to investigational medicines. Join us at the Europe EAP Summit on October 8, 2024, in London to hear a family’s inspiring 5-year journey.

Join us at the 3rd Operationalize Expanded Access Programmes Summit Europe, 7-9 Oct 2024, at Millennium Gloucester Hotel, London. Learn about program setup, regulatory pathways, data collection, real-world data, exit strategies, and patient support.

EARLY ACCESS CARE IS AN EXHIBITING SPONSOR OF ASCO IN 2024

Early Access Care will be participating at the Operationalize Expanded Access Programs on March 19 - 21, 2024 in Boston, MA. Join colleagues across the pharmaceutical industry as they come together to share ideas and learn about Expanded Access, Compassionate Use, and Post Trial Access programs.

The ESMO Annual Meeting 2023 Congress (Madrid, 20-24 October) is now over, and we summarized lessons learned for compassionate use and expanded access programs – enabling new and familiar science into compassionate use programs...

Early Access Care – Innovation in pre-approval access. We’re leading the path forward...

Early Access Care is excited to annouce the upgrade of the earlyaccesscare.com Website! We have expanded our features to include Frequently Asked Questions as well as Glossary Terms. Take a loook around!

We look forward to speaking with attendees at ASCO '23 about Expanded Access Program options. Visit at Booth 11091!

There has been a global increase in the use of smart phones and wearables such as FitBits and Apple Watches. Online visits with medical providers and e-portals such as MyChart have become common place. There are many applications available that continuously and effortlessly capture data to aid in...

Post-Trial Expanded Access - An FDA Statement Transitioning patients from a clinical trial or Open Label Extension (OLE) study can pose opportunities and reduce burden to pharmaceutical companies. The term "post-trial" access is the provision of investigational medications...

Last week, at the 2022 Annual Meeting of the American Society for Clinical Oncology a question we were commonly asked was to define an Expanded Access Programs (EAP) and compare and contrast with a compassionate use program (CUP). An EAP allows physicians and patients to access...